132 related articles for article (PubMed ID: 34265779)
21. A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes.
Tkáč I; Javorský M; Klimčáková L; Židzik J; Gaľa I; Babjaková E; Schroner Z; Štolfová M; Hermanová H; Habalová V
Eur J Clin Pharmacol; 2015 Jan; 71(1):59-63. PubMed ID: 25327507
[TBL] [Abstract][Full Text] [Related]
22. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
Goldstein BJ; Pans M; Rubin CJ
Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
[TBL] [Abstract][Full Text] [Related]
23. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.
Goswami S; Yee SW; Stocker S; Mosley JD; Kubo M; Castro R; Mefford JA; Wen C; Liang X; Witte J; Brett C; Maeda S; Simpson MD; Hedderson MM; Davis RL; Roden DM; Giacomini KM; Savic RM
Clin Pharmacol Ther; 2014 Sep; 96(3):370-9. PubMed ID: 24853734
[TBL] [Abstract][Full Text] [Related]
24. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
25. No significant association of type 2 diabetes-related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives.
Martono DP; Heerspink HJL; Hak E; Denig P; Wilffert B
Diabetes Obes Metab; 2019 Oct; 21(10):2267-2273. PubMed ID: 31168905
[TBL] [Abstract][Full Text] [Related]
26. The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Kashi Z; Mahrooz A; Kianmehr A; Alizadeh A
PLoS One; 2016; 11(3):e0151543. PubMed ID: 26978661
[TBL] [Abstract][Full Text] [Related]
27. The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
Kashi Z; Masoumi P; Mahrooz A; Hashemi-Soteh MB; Bahar A; Alizadeh A
Diabetes Res Clin Pract; 2015 Apr; 108(1):78-83. PubMed ID: 25662675
[TBL] [Abstract][Full Text] [Related]
28. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
29. Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.
Polidori D; Capuano G; Qiu R
Diabetes Obes Metab; 2016 Apr; 18(4):348-54. PubMed ID: 26661906
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
Mofo Mato EP; Guewo-Fokeng M; Essop MF; Owira PMO
Medicine (Baltimore); 2018 Jul; 97(27):e11349. PubMed ID: 29979413
[TBL] [Abstract][Full Text] [Related]
31. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.
Bermúdez-Pirela VJ; Cano C; Medina MT; Souki A; Lemus MA; Leal EM; Seyfi HA; Cano R; Ciscek A; Bermúdez-Arias F; Contreras F; Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):194-202. PubMed ID: 17414590
[TBL] [Abstract][Full Text] [Related]
32. Predictors of HbA1c levels in patients initiating metformin.
Martono DP; Hak E; Lambers Heerspink H; Wilffert B; Denig P
Curr Med Res Opin; 2016 Dec; 32(12):2021-2028. PubMed ID: 27552675
[TBL] [Abstract][Full Text] [Related]
33. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
Sun W; Zeng C; Liao L; Chen J; Wang Y
Curr Med Res Opin; 2016 Aug; 32(8):1389-96. PubMed ID: 27052634
[TBL] [Abstract][Full Text] [Related]
34. [Detection of LADA-type diabetes in overweight diabetic patients. Is treatment with metformin suitable?].
Lóriz Peralta O; Campos Bonilla B; Granada Ybern ML; Sanmartí Sala A; Arroyo Bros J;
Aten Primaria; 2007 Mar; 39(3):133-7. PubMed ID: 17386205
[TBL] [Abstract][Full Text] [Related]
35. Evidence of a threshold value of glycated hemoglobin to improve the course of renal function in type 2 diabetes with typical diabetic glomerulopathy.
Brocco E; Velussi M; Cernigoi AM; Abaterusso C; Bruseghin M; Carraro A; Sambataro M; Piarulli F; Sfriso A; Nosadini R
J Nephrol; 2001; 14(6):461-71. PubMed ID: 11783602
[TBL] [Abstract][Full Text] [Related]
36. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
[TBL] [Abstract][Full Text] [Related]
37. A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations.
Gadgade A; Kudgi AS; Kamath A; Kamath P; Adhikari P; Revappala NS; Hadigal S; Natarajan S; Shenoy N; Chowta MN
Curr Diabetes Rev; 2020; 16(5):503-508. PubMed ID: 31250763
[TBL] [Abstract][Full Text] [Related]
38. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
39. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
Ross SA; Caballero AE; Del Prato S; Gallwitz B; Lewis-D'Agostino D; Bailes Z; Thiemann S; Patel S; Woerle HJ; von Eynatten M
Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
